Home › Funds › Parkman Healthcare Partners LLC › CDNA
Parkman Healthcare Partners LLC position in CDNA
CAREDX INC · Health Care
Parkman Healthcare Partners LLC reported holding 200,410 shares of CDNA (CAREDX INC) in its Q3 2026 13F filing — a position valued at US$13.0M, representing 1.18% of its reported portfolio and ranking #34 among its reported holdings. Parkman Healthcare Partners LLC has disclosed CDNA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's CDNA position evolved
Parkman Healthcare Partners LLC first disclosed a stake in CDNA in Q4 2025 at 276,154 shares (US$5.2M). The position peaked in Q3 2026 at 200,410 shares, worth US$13.0M. Across 4 filings, Parkman Healthcare Partners LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 200,410 shares valued at US$13.0M — a reduction of -2,007 shares quarter over quarter.. Notable position changes include a 31% trim in Q2 2026 (shares rose 128% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 276.15K | $5.20M | New |
| Q1 2026 | 291.38K | $5.06M | Add |
| Q2 2026 | 202.42K | $5.77M | Reduce |
| Q3 2026 | 200.41K | $13.03M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CDNA and 13F data
CDNA (CAREDX INC) is a Health Care company. 51 other funds we track also report a position in CDNA — the largest reported positions include Blue Water Life Science Advisors, LP (US$113.1M), ARK Invest (US$104.6M), GAGNON SECURITIES LLC (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CDNA
- Blue Water Life Science Advisors, LP 1.74M sh · $113.10M · Q3 2026
- ARK Invest 1.61M sh · $104.59M · Q3 2026
- GAGNON SECURITIES LLC 1.07M sh · $69.84M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 2.00M sh · $56.93M · Q2 2026
- Amova Asset Management Americas, Inc. 625.42K sh · $40.63M · Q3 2026
- Ophir Asset Management Pty Ltd 582.41K sh · $37.86M · Q3 2026
- BRAIDWELL LP 1.22M sh · $34.79M · Q2 2026
- Zweig-DiMenna Associates LLC 389.81K sh · $25.34M · Q3 2026
- Divisadero Street Capital Management, LP 700.94K sh · $19.98M · Q2 2026
- Portolan Capital Management, LLC 684.80K sh · $19.52M · Q2 2026
- Gagnon Advisors, LLC 286.89K sh · $18.65M · Q3 2026
- Palo Alto Investors LP 531.87K sh · $15.16M · Q2 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held CDNA?
Parkman Healthcare Partners LLC has disclosed CDNA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Parkman Healthcare Partners LLC's current position in CDNA?
As of Q3 2026, Parkman Healthcare Partners LLC holds 200.41K shares of CDNA (CAREDX INC), valued at $13.03M, representing 1.18% of its reported portfolio and ranking #34.
Has Parkman Healthcare Partners LLC been buying or selling CDNA?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC reduced its position in CDNA. The position peaked in Q3 2026 at 200.41K shares.
Which other funds hold CDNA?
Other major institutional holders of CDNA include Blue Water Life Science Advisors, LP, ARK Invest, GAGNON SECURITIES LLC, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.